

GASTROENTEROLOGY**PAPER-III**Time: 3 hours
Max. Marks: 100

GASTRO/D/19/10/III

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Staging of Hepatocellular Carcinoma (HCC). 3+3+4
b) Post TACE syndrome.
c) Recent advances in systemic therapy in HCC.
2. a) Minimal hepatic encephalopathy (MHE) - definition. 2+3+5
b) Tests for diagnosis of MHE.
c) Management of MHE.
3. a) Normal gut flora. 3+4+3
b) Indications for Fecal Microbiota Transplantation (FMT).
c) Complications of FMT.
4. a) WHO classification of Primary tumours of the Exocrine Pancreas. 3+3+4
b) Resectability in Carcinoma Pancreas.
c) Management of unresectable Carcinoma Pancreas.
5. a) Lifestyle changes in management of NAFLD. 3+3+4
b) Newer drugs in NAFLD treatment.
c) Genetics of NAFLD.
6. a) Clinical features of Whipple's disease. 3+3+4
b) Diagnosis of Whipple's disease.
c) Management of Whipple's disease.
7. a) Types of Lumen apposing metallic stents in GI practice. 3+4+3
b) Indications for Lumen apposing metallic stents.
c) Complications of Lumen apposing metallic stents.
8. a) Surveillance in post colectomy Familial Adenomatous Polyposis syndrome patients. 5+5
b) Chemoprevention of Colorectal Carcinoma.

P.T.O

GASTROENTEROLOGY**PAPER-III**

9. a) Transient elastography in NAFLD. 3+4+3
b) Noninvasive serum markers for fibrosis of liver.
c) Indications for liver biopsy in NAFLD.
10. a) Biosimilar in Gastroenterology practice. 4+3+3
b) Various formulations of mesalamine.
c) Therapeutic drug monitoring for Anti TNF agents in IBD.
